实用肝脏病杂志Issue(1)：33-36,4.DOI:10.3969/j.issn.1672-5069.2016.01.009
干扰素α-1b联合恩替卡韦治疗高病毒载量慢性乙型肝炎疗效评价
Efficacy of interferon alfa-1b combined with entecavir in treatment of patients with chronic hepatitis B and high serum viral load
占国清 1李芳 1李儒贵 1刘翔 1谭华炳1
作者信息
- 1. 442000 湖北省十堰市 湖北医药学院附属人民医院肝病研究所
- 折叠
摘要
Abstract
Objective To investigate the clinical efficacy of interferon alfa-1b combined with entecavir (ETV)in treatment of patients with chronic hepatitis B (CHB) and high serum viral loads. Methods 92 patients with CHB and high serum viral load (HBV DNA≥1×107 IU/ml) were divided into observation group (n=48) and control group (n=44). Patients in the control group were treated with interferon alfa-1b,and patients in the observation group were treated with interferon alfa-1b combined with ETV. The treatment course in two groups lasted for 48 weeks. The recovery rates of serum alanine aminotransferase (ALT),rates of serum HBV DNA loss, negative rates of HBeAg and the conversion rates of HBeAg to anti-HBe were compared at 12,24 and 48 weeks. Serum HBV markers and HBV DNA levels were routinely detected. Results The recovery rates of serum ALT at week 24 and 48 in observation group were 68.8% and 91.7%,respectively,significantly higher than those in the control group (34.1% and 63.6%,P<0.01);The negative rates of serum HBV DNA at week 12,24 and 48 in the observation group were 45.8%,72.9% and 87.5%,respectively,which were significantly higher than those in the control group (11.4%,31.8% and 47.7%,P<0.01);The negative rate of HBeAg and the conversion rate of serum HBeAg at the end of week 48 in the observation group were 67.6% and 62.2%,significantly higher than those in the control group (42.9% and 37.1%,P<0.05). Conclusion Efficacy of interferon alfa-1b combined with ETV in treatment of patients with CHB and high serum viral load is superior to IFN alfa-1b monotherapy.关键词
慢性乙型肝炎/干扰素α-1b/恩替卡韦/高病毒载量/疗效Key words
Chronic hepatitis B/Interferon alfa-1b/Entecavir/Serum viral loads/Therapeutic efficacy引用本文复制引用
占国清,李芳,李儒贵,刘翔,谭华炳..干扰素α-1b联合恩替卡韦治疗高病毒载量慢性乙型肝炎疗效评价[J].实用肝脏病杂志,2016,(1):33-36,4.
